Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orencia
Pharma
J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD
Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease.
Kevin Dunleavy
Aug 25, 2022 9:37am
Docs turning to Bristol's aging Orencia amid JAK safety woes
Apr 13, 2022 9:30am
BMS's Orencia wins FDA nod for prevention of GVHD
Dec 15, 2021 3:25pm
BMS' Orencia snagged priority review in transplant rejection
Aug 23, 2021 11:02am
NIH tests J&J, BMS and AbbVie drugs in new COVID-19 trial
Oct 16, 2020 11:06am
Abbvie's Rinvoq matches BMS' Orencia in head-to-head RA trial
Jun 8, 2020 9:44am
